Cargando…
Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States
The utilization of trastuzumab biosimilar medications is of particular interest in HER2-positive breast cancer as these drugs have the potential for cost savings and increased utilization/access to HER2 targeted therapy in both early stage and metastatic HER2-positive breast cancers. Five trastuzuma...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859678/ https://www.ncbi.nlm.nih.gov/pubmed/31798693 http://dx.doi.org/10.1177/1758835919887044 |